Good News | Baishixing Technology Secures Another Invention Patent and Participates in Drafting the "Specifications for the Construction of Pilot-Scale Platforms for Chemical Drugs" Series of Group Standards

In the biopharmaceutical industry chain, the independent R&D and standardization of core raw materials serve as the twin engines driving high-quality development. Recently, Chengdu Baishixing Technology Industrial Co., Ltd. achieved a double success: it secured an invention patent for "A Synthesis Method for Glycyl-L-Tyrosine" and played a pivotal role—as a core drafting entity—in formulating the "Specifications for the Construction of Pilot-Scale Platforms for Chemical Drugs" series of group standards. This high-tech enterprise, specializing in protected amino acids, oligopeptides, and cell culture medium raw materials, is demonstrating its innovation capabilities through solid technical strength.

1,Core Business: Focusing on Key Raw Materials for Life Sciences

Chengdu Baishixing Technology Industrial Co., Ltd. is a high-tech enterprise integrating the R&D, production, and sales of protected amino acids, oligopeptides, cell culture medium raw materials, bioactive substances, and pharmaceutical intermediates. Deeply rooted in this niche sector, the company is dedicated to supplying high-quality core raw materials to the global biopharmaceutical, cell therapy, and diagnostic reagent industries.

2,Technological Breakthrough: Invention Patent Granted for Glycyl-L-Tyrosine Synthesis Method

The glycyl-L-tyrosine associated with this newly granted patent is a vital component of cell culture media; it provides essential nutritional support during cell culture and constitutes an indispensable link in the upstream biopharmaceutical supply chain.

Technical Value: This synthesis method optimizes reaction pathways and purification processes, significantly enhancing product purity and batch-to-batch stability while simultaneously reducing production costs.

Industrial Significance:As a key component of cell culture media, the quality of glycyl-L-tyrosine directly impacts cell growth and protein expression efficiency. Securing this patent marks a further strengthening of Baishixing Technology’s competitive technical edge in the field of cell culture medium raw materials.

3,Standard Setting: Deep Involvement in Pilot-Scale Platform Development

Beyond breakthroughs in product R&D, Chengdu Baishixing Technology actively participates in the development of industry infrastructure. The company has collaborated with entities such as Chengdu Tongde Pharmaceutical Co., Ltd., Sichuan Debo'er Pharmaceutical Co., Ltd., the West China School of Pharmacy at Sichuan University, and Chengdu University of Traditional Chinese Medicine to draft three group standards:

* *Specifications for the Construction of Pilot-Scale Platforms for Chemical Drugs – Part 1: General Principles*: Aims to establish principles, construction requirements, and operational management requirements for chemical drug pilot-scale platforms.

* *Specifications for the Construction of Pilot-Scale Platforms for Chemical Drugs – Part 2: Technology Transfer*: Aims to establish the processes and requirements for technology transfer within chemical drug pilot-scale platforms.

* *Specifications for the Construction of Pilot-Scale Platforms for Chemical Drugs – Part 3: Data and Traceability Management*: Aims to establish requirements for data management and traceability during the execution of pilot-scale projects.

Why establish these standards?

Pilot-scale platforms serve as the bridge between laboratory R&D and industrial-scale production. By establishing standardized practices for platform construction, technology transfer, and data/traceability management, these platforms gain a clear operational framework. This enhances pilot-scale capabilities and service effectiveness, fosters the functional development of these platforms, and better promotes the deep integration of scientific and industrial innovation. As an enterprise with extensive production experience, Baishixing Technology has distilled years of practical expertise into these standards, contributing "Baishixing wisdom" to improving technology transfer efficiency across the entire industry.

4. Proven Expertise: 32 Patents and Multiple Technologies

Filling Domestic Gaps

To date, Chengdu Baishixing holds a total of 16 invention patents and 16 utility model patents, with multiple technologies filling gaps in the domestic market. In specialized sectors such as the protection of amino acids, oligopeptides, and raw materials for cell culture media, the performance of several products has reached an advanced international level, gradually enabling import substitution.

5. Looking to the Future

From the independent R&D of core raw materials to the collaborative establishment of standards for pilot-scale platforms, Chengdu Baishixing Technology has consistently driven its growth through innovation. Moving forward, the company will continue to deepen its presence in the fields of protected amino acids and cell culture media raw materials. By leveraging standardized pilot-scale platforms to accelerate the commercialization of research outcomes, Baishixing aims to supply superior, highly stable core raw materials to the global life sciences research community and the biopharmaceutical industry. Technological innovation knows no bounds, and Baishixing remains steadfast on this journey of progress.